PhoenixBio Co., Ltd.

TSE:6190 Stock Report

Market Cap: JP¥1.5b

PhoenixBio Past Earnings Performance

Past criteria checks 3/6

PhoenixBio's earnings have been declining at an average annual rate of -10.1%, while the Life Sciences industry saw earnings declining at 8.6% annually. Revenues have been growing at an average rate of 3% per year. PhoenixBio's return on equity is 8.1%, and it has net margins of 8%.

Key information

-10.15%

Earnings growth rate

-5.94%

EPS growth rate

Life Sciences Industry Growth32.01%
Revenue growth rate2.97%
Return on equity8.05%
Net Margin7.99%
Next Earnings Update14 Aug 2026

Recent past performance updates

Recent updates

Analysis Article • Dec 01

Is PhoenixBio (TSE:6190) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Aug 05

Is PhoenixBio (TSE:6190) A Risky Investment?

TSE:6190 1 Year Share Price vs Fair Value Explore PhoenixBio's Fair Values from the Community and select yours Some say...
Analysis Article • Apr 07

PhoenixBio Co., Ltd. (TSE:6190) Looks Inexpensive After Falling 33% But Perhaps Not Attractive Enough

PhoenixBio Co., Ltd. ( TSE:6190 ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Feb 19

PhoenixBio Co., Ltd.'s (TSE:6190) Shares Bounce 31% But Its Business Still Trails The Industry

PhoenixBio Co., Ltd. ( TSE:6190 ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Nov 18

PhoenixBio Co., Ltd.'s (TSE:6190) Share Price Is Matching Sentiment Around Its Revenues

With a price-to-sales (or "P/S") ratio of 0.8x PhoenixBio Co., Ltd. ( TSE:6190 ) may be sending bullish signals at the...

Revenue & Expenses Breakdown

How PhoenixBio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:6190 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 261,565125915191
31 Dec 251,598-205892273
30 Sep 251,509-312894273
30 Jun 251,492-452927273
31 Mar 251,541-448971273
31 Dec 241,530-1381,056206
30 Sep 241,622-1251,046206
30 Jun 241,72571,033206
31 Mar 241,71526975206
31 Dec 231,792114923205
30 Sep 231,870164907205
30 Jun 232,118432869205
31 Mar 232,124493836205
31 Dec 222,051167800219
30 Sep 221,82299746219
30 Jun 221,317-348686219
31 Mar 221,324-387665219
31 Dec 211,445-52621221
30 Sep 211,349-101614221
30 Jun 211,303-53628221
31 Mar 211,013-238636221
31 Dec 20978-578666238
30 Sep 201,090-526704238
30 Jun 201,184-458723238
31 Mar 201,310-415765238
31 Dec 191,231-220717345
30 Sep 191,323-202773345
30 Jun 191,358-210805345
31 Mar 191,228-297809345
31 Dec 181,087-303852176
30 Sep 181,012-300767176
30 Jun 18937-297676176
31 Mar 18902-270593176
31 Dec 17974-167601140
30 Sep 17987-60566140
30 Jun 171,014-13554140
31 Mar 171,228128552140
31 Dec 161,317121584146
31 Mar 161,217125488146

Quality Earnings: 6190 has high quality earnings.

Growing Profit Margin: 6190 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6190 has become profitable over the past 5 years, growing earnings by -10.1% per year.

Accelerating Growth: 6190 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 6190 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-16.4%).

Return on Equity

High ROE: 6190's Return on Equity (8.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 18:31
End of Day Share Price 2026/06/15 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PhoenixBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.